Next Article in Journal
Supramolecular Detection of a Nerve Agent Simulant by Fluorescent Zn–Salen Oligomer Receptors
Previous Article in Journal
Optimization of Pectin Enzymatic Extraction from Malus domestica ‘Fălticeni’ Apple Pomace with Celluclast 1.5L
Open AccessArticle

Conformational Studies of Glucose Transporter 1 (GLUT1) as an Anticancer Drug Target

1
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA
2
Department of Chemistry, University of Nebraska at Omaha, Omaha, NE 68182, USA
*
Author to whom correspondence should be addressed.
Molecules 2019, 24(11), 2159; https://doi.org/10.3390/molecules24112159
Received: 21 May 2019 / Revised: 5 June 2019 / Accepted: 5 June 2019 / Published: 7 June 2019
(This article belongs to the Section Computational and Theoretical Chemistry)
Glucose transporter 1 (GLUT1) is a facilitative glucose transporter overexpressed in various types of tumors; thus, it has been considered as an important target for cancer therapy. GLUT1 works through conformational switching from an outward-open (OOP) to an inward-open (IOP) conformation passing through an occluded conformation. It is critical to determine which conformation is preferred by bound ligands because the success of structure-based drug design depends on the appropriate starting conformation of the target protein. To find out the most favorable GLUT 1 conformation for ligand binding, we ran systemic molecular docking studies for different conformations of GLUT1 using known GLUT1 inhibitors. Our data revealed that the IOP is the preferred conformation and that residues Phe291, Phe379, Glu380, Trp388, and Trp412 may play critical roles in ligand binding to GLUT1. Our data suggests that conformational differences in these five amino acids in the different conformers of GLUT1 may be used to design ligands that inhibit GLUT1. View Full-Text
Keywords: glucose transporter 1 (GLUT1); conformation; docking; anticancer; drug design glucose transporter 1 (GLUT1); conformation; docking; anticancer; drug design
Show Figures

Figure 1

MDPI and ACS Style

Almahmoud, S.; Wang, X.; Vennerstrom, J.L.; Zhong, H.A. Conformational Studies of Glucose Transporter 1 (GLUT1) as an Anticancer Drug Target. Molecules 2019, 24, 2159.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop